Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8777MR)

This product GTTS-WQ8777MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8777MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6788MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ21MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ3236MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ2680MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ6693MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ9649MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ10481MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ7506MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW